According to filings with the U.S. Securities and Exchange Commission, Oisin Biotechnologies is raising up to $17,879,999.00 in new funding. Sources indicate that as part of senior management President, Matthew Scholz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oisin Biotechnologies
Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. Its believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they dont. They become zombie cells unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisin Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

To learn more about Oisin Biotechnologies, visit http://www.oisinbio.com/
Oisin Biotechnologies Linkedin Page: https://www.linkedin.com/company/oisin-biotechnologies/

Contact:
Matthew Scholz, President
206-880-1166
https://www.linkedin.com/in/matthewscholz/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.